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To klentii the effect of Lpmpionykamitine 
(WC) on ischemia, 31 fastin& untreated male 
patients with left coronary artery disease were 
studied during 2 identical pacing stress tests 45 
minutes before (atrial pacing test I [APST I]) and 
15 minutes after (APST II) administration of 15 
mg/kg of WC or placebo. Hemodynamic, 
metabolic, and nuclear angiographic variables 
were studied before, durin& and for 10 minutes 
after pachtg. After WC administration, arterial 
total camitine levels imxeased from 47 f 1.7 
pmol/liter (control) to 730 + 30 pmol/liter. 
Hemodynamic and metabolic variables were com- 
parable in LPC and placebo during APST I, and 
reproducible in placebo during both tests. Al- 
though LPC did not affect myocardial oxygen de- 
mand and supply, it diminished myocardial ische- 
mia, indicated by a significant 12% and 50% 
reduction in ST-segment depression and left ven- 
tricular en&diastolic pressure, respectively, dur- 
ing APST II. Moreover, during APST II, left ven- 
tricular ejection fraction increased by 18% (p 
<0.05 vs APST I). Furthermore, LPC improved re- 
covery of myocardial function after pa&g, with 
a reduction in the time to peak filling and a 21% 
increase in both peak ejection and filling rates 
10 minutes after pacing (all p eO.05). lhus, LPC 
prevents ischemiainduced ventricular dysfu~ 
tion, not by affecting the myocardial oxygen sup 
ply-demand ratio but as a result of its intrinsic 
metabolic actions, increasing pyruvate dehydro- 
genase activity and flux through the citric acid 
cycle. Because it is well tolerated, it may be a 
valuable attemative or addition to available anti- 
ischemic therapy. 
(Am J Cardiol1994;74:12Sl30) 
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B ecause available anti-ischemic agents are often in- adequate due to incomplete fficacy or adverse f- fects, there is a need for alternative pharmaco- 
logic strategies (e.g., metabolic anti-ischemic therapy). 
L-carnitine mediates mitochondrial fatty acid transport 
and regulates mitochondrial high-energy phosphate x- 
change through the activity of adenine nucleotide trans- 
locase.‘,* Moreover, it stimulates pyruvate dehydro- 
genase and improves the flux of pyruvate into the citric 
acid cycle.3 As the heart is unable to synthesize L-car- 
nitine, it is critically dependent on external suppl~.~J 
During ischemia, total and free myocardial carnitine lev- 
els decrease.6,7 In addition, acyl coenzyme A (CoA) ac- 
cumulates and inhibits adenine nucleotide translocase 
and pyruvate dehydrogenase activity. Administration of 
L-camitine may reverse this inhibition.’ In both animals 
and humans, anti-ischemic effects of L-carnitine have 
been reported. su L-propionylcarnitine (LPC), a natural 
derivative of L-camitine, may be more effective in this 
respect, because it is more rapidly accessible to the car- 
diocyte1*,13 and may increase the citric acid flux through 
newly formed propionyl-CoA.t4 Indeed, animal models 
of ischemia-reperfusion indicate a protective ffect of in- 
travenous LPC.15*16 Because no human data are avail- 
able, the present study evaluated the anti-ischemic ef- 
fects of intravenous LPC in patients with coronary artery 
disease. 
METHODS 
Patients: After approval of the institutional ethical 
review board and informed consent, 31 normotensive 
male patients aged 46 to 73 years (mean 57) with an- 
gina pectoris and objective signs of exercise-induced is- 
chemia were evaluated. Twenty patients had a docu- 
mented myocardial infarction. Patients with unstable 
angina, arterial hypertension (systolic pressure >220 mm 
Hg, diastolic pressure >lOO mm Hg), symptoms or signs 
of congestive heart failure, conduction abnormalities, 
valvular heart disease, diabetes mellitus, and renal or 
hepatic dysfunction were excluded. Previous myocardial 
infarctions had to be at least 1 month old. All cardiac 
medication was withheld 24 to 72 hours before the in- 
vestigation. Only short-acting nitroglycerin was allowed 
until 6 hours before the study. None of the patients re- 
ceived digitalis. To participate, patients had to have a di- 
ameter stenosis of 270% in either the left anterior de- 
scending artery, a diagonal branch, the proximal part of 
the left circumflex artery, or a proximal marginal branch. 
Nine patients had l-vessel, 11 patients 2-vessel, and 11 
patients 3-vessel disease. 
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TABLE I Baseline Characteristics of Patients 
L-Propionylcarnitine Placebo 
Number of patients 15 16 
Age (years) 59*2 58*2 
Previous myocardial infarction 13* 7 
Anterior 6 3 
Inferior 8 4 
Number of coronary arteries 
narrowed >70% in diameter 
1 6 3 
2 3 8 
3 6 5 
Left ventricle 
End-diastolic volume (mllmz) 73 f 6 62i5 
Ejection fraction (%) 43+4 50*3 
*p co.05 L-propionylcarnitine versus placebo. 
Data are mean f SEM. 
Instrumentation: Studies were conducted in the 
morning, without premeditation and with the patient 
fasting. First, left and right coronary angiography was 
performed, using the Seldinger technique. If patients met 
the inclusion criteria, a no. 7Fr thermodilution flow and 
pacing catheter (Wilton Webster Laboratories) was ad- 
vanced into the midportion of the coronary sinus through 
a brachial vein so that its position was stable and blood 
could be drawn easily. The absence of atria1 reflux was 
confirmed by bolus injections of saline solution at room 
temperature in the right atrium. Next, a no. 7Fr triple- 
lumen thermodilution catheter was positioned in a pul- 
monary artery through the right femoral vein and a no. 
8Fr Sentron pigtail microtip manometer catheter ad- 
vanced into the left ventricle through a no. 9Fr Desilet 
introducer system in the right femoral artery. The side 
arm of the latter was used to monitor arterial pressures. 
The position of the catheters was recorded on video and 
checked throughout he study. 
Hemodynamic and electrocardiographic mea 
surements: All fluid-filled catheters were calibrated us- 
ing a zero reference level set at midchest. Pressures in 
the right atrium and in the femoral and pulmonary ar- 
teries were measured using Bentley transducers (Baxter- 
Bentley, Uden, The Netherlands). All pressures were 
recorded on paper at different paper speeds (i.e., at 10, 
25, and 100 mm/s) using a Nihon Kohden cath lab sys- 
tem. In addition, pressure-derived contractility and re- 
laxation indexes were determined on-line by a Mennen 
cath lab computer system. In a beat-to-beat nalysis, this 
system averages 15 to 20 consecutive beats to level out 
respiratory variations. Coronary sinus blood flow was 
determined uring a continuous 30-second infusion of 
50 ml of 5% glucose at room temperature.” Electrocar- 
diographic leads I, B, and V, were continuously moni- 
tored. The ST-segment level was assessed with a cali- 
brated magnifying lens in 5 consecutive beats 0.08 
second after the J point at a paper speed of 100 mm/s. 
Metabolic measurements: Blood sampling for 
metabolic determinations was performed simultaneously 
from the left ventricle and the coronary sinus. Oxygen 
saturation was determined with an OSM-80 oximeter 
(Waters Associates). For lactate, exactly 1 ml was sam- 
pled in 2 ml of ice cold 0.6 M perchloric acid, and an- 
alyzed as previously reported.‘* Blood samples (1 ml) 
for hypoxanthine analysis were collected in precooled 
heparinized tubes containing 0.5 ml of 40 pM of dipyrid- 
amole and 0.5 ml of 20 pM of erythro-9-(2-hydroxy-3- 
nonyl) adenine. Hypoxanthine was assayed by dual-col- 
umn high-pressure liquid chromatography asreported. l8 
The standard eviation is 0.2 pM. For the analysis of 
free and total L-carnitine, 2 ml of arterial blood was col- 
lected in precooled tubes containing 500 IU of heparin. 
Free L-carnitine was determined by radioenzymatic 
assay (SD = 0.8 pmol/liter) and total L-camitine, after 
hydrolysis by 0.1 M potassium hydroxide and neutral- 
ization with 0.5 M N-[2-hydroxyethyllpiperazine-N’- 
[Zethanesulfonic acid], was determined radioenzymat- 
ically (SD = 1.0 pmol/liter).i9 
Scintigraphic measurements: After in vivo label- 
ing with 1,000 MBq of technetium-99m, radionuclide 
angiography was performed in a 35” to 40” left anterior 
oblique projection with an approximate 10” cranial tilt 
using a mobile LEM gamma camera (Siemens) equipped 
with a low-energy, all-purpose collimator, and connected 
on-line with a mobile MCS/560 nuclear computer sys- 
tem (General Electric). A 20% window was set around 
the 140 KeV gamma peak and data were collected in a 
64 X 64 matrix using a 1.5X zoom. Framing intervals 
were calculated to produce 16 frames/cycle. Cardiac cy- 
cles, with a cycle length that differed >lO% from the av- 
erage cycle length recorded just before acquisition, were 
automatically excluded from analysis. Imaging lasted 8 
minutes at baseline and 4 minutes during pacing and af- 
ter pacing. Data analysis was performed with a Sophy P 
computer (Sopha Medical) using the methods described 
by Magorien et al. *O The following variables were de- 
termined: left ventricular ejection fraction (%), wall mo- 
tion changes (25% points change in 9 sectorial ejection 
fractions), time to peak filling and ejection rate (ms), and 
peak ejection and filling rate (sec.‘). 
Drug administration: Patients received either LPC 
(15 mg/kg) or its vehicle (15 mg/kg mannitol and 19.5 
mg/kg sodium anhydrous in 0.25 mg/kg distilled water) 
over a 5-minute period in a double-blind, randomized 
fashion. 
Study protocol: After instrumentation, a stabiliza- 
tion period of 220 minutes was allowed to achieve a 
minimal interval of 45 minutes between coronary an- 
giography and the study. Multiple control determinations 
of all hemodynamic variables were then performed to 
ensure stable baseline values. Next, the first atria1 pac- 
ing stress test (APST I) was performed, with increments 
in heart rate of 10 beats/2 minutes, until angina, atri- 
oventricular block, or a maximal heart rate of 170 
beats/min was reached. Forty-five minutes after APST 
I, after reassessing hemodynamic, scintigraphic, and 
metabolic variables, patients received either LPC or ve- 
hicle. Twenty minutes after the onset of drug infusion, 
a second atria1 pacing stress test (APST II), identical to 
APST I, was performed. During both tests, hemody- 
namic variables, lactate, and oxygen were determined at 
baseline, maximal pacing, and at 15 seconds, 1, and 10 
minutes after pacing. Hypoxanthine levels were deter- 
mined at control, maximal pacing, and 1 minute after 
pacing. Arterial carnitine levels were determined before 
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and 5, 15, and 45 minutes after the start of the drug in- 
fusion. 
Data analysis: Data are presented as mean + SEM. 
The statistical analysis consisted of a t test for paired ob- 
servations and an analysis of variance to differentiate be- 
tween group differences at the respective time points. A 
2-tailed p value <0.0.5 was considered a significant dif- 
ference. 
RESULTS 
LPC was administered to 15 patients and placebo to 
16 patients. Baseline clinical and demographic data are 
listed in Table I. Both groups were comparable as to age, 
sex, number of coronary lesions, and left ventricular 
function. Old myocardial infarctions were present in 13 
patients in the LPC group versus 7 in the placebo group 
(p <0.05). 
llemodynamic and electrocardiographic changes 
during pacing: Baseline systemic and coronary hemo- 
dynamic variables were comparable in both groups (Ta- 
bles II and III). In the placebo group, APST I resulted 
in myocardial ischemia indicated by ST-segment de- 
pression of -0.15 If: 0.03 mV, and an increase in left 
ventricular end-diastolic pressure from 14 f 1 (baseline) 
to 21 f 2 mm Hg immediately after pacing (Figure 1). 
All parameters returned to baseline values between 5 and 
10 minutes after pacing. During APST II, baseline val- 
ues and changes in hemodynamic and electrocardio- 
graphic parameters were similar to those observed dur- 
ing APST I in placebo-treated patients. 
In the LPC group, changes during and after APST I 
were similar to those in the placebo patients, except for 
cardiac index, which was still significantly reduced in 
the LPC group 30 minutes after pacing. Hemodynamic 
changes were comparable during both pacing tests. In 
contrast to placebo, LPC reduced left ventricular end-di- 
astolic pressure after pacing by 50% (Figure 1) and re- 
sulted in a moderate but significant reduction in ST-seg- 
ment depression during APST II, whereas the decrease 
in cardiac index after APST I was prevented after APST 
II (all p ~0.05, APST II vs I). 
Metabolic changes: At baseline, myocardial lactate 
and hypoxanthine extraction values were comparable in 
both groups (Table III). In the placebo group, a signifi- 
cant but reproducible cardiac release of both metabolites 
was observed. During APST I, similar changes occurred 
in the LPC group. At the start of APST II, 15 minutes 
after LPC administration, myocardial lactate extraction 
had increased by 24%. Whereas myocardial lactate pro- 
duction was comparable during both tests in LPC, the 
change from hypoxanthine uptake to release was signif- 
icantly less during APST II. 
Scintigraphic determinations: At baseline, all vari- 
ables were comparable in both groups (Table IV). Also, 
changes in peak ejection and filling rate during APST I 
were comparable in both groups, and during both tests 
in the placebo group. In the latter, left ventricular ejec- 
tion fraction did not change throughout the study. In con- 
trast, it increased by 18% during APST II after LPC (p 
<0.05), together with a significant wall motion score im- 
provement in all but 2 patients. Moreover, and in con- 
trast to the placebo group, LPC improved recovery of 
myocardial function after pacing with a 21% increase in 
peak ejection and peak filling rate and a reduction in time 
to peak filling (-42 ms) 10 minutes after pacing com- 
pared with results after APST I (p ~0.05). 
Camitine plasma levels: The baseline plasma lev- 
els of free and total camitine were similar in placebo (35 
f 1.7 and 46 f 1.6 pmol/liter, respectively) and LPC (36 
k 1.5 and 47 + 1.7 p.mol/liter, respectively) groups. In 
the placebo group, arterial levels of total and free carni- 
tine remained unaltered throughout the study. In the 
treated group, the plasma level of total camitine in- 
creased 15-fold immediately after the infusion of 15 
mg/kg of LPC, but subsequently decreased to 5 times 
the baseline level 10 minutes after pacing, approximately 
40 minutes after drug administration (Figure 2). Free car- 
nitine levels increased four- to fivefold, and decreased 
to 92 f 6 ymol/liter, 2.5 times baseline levels at the end 
of the study. 
Adverse effects: None of the patients experienced 
any adverse effects. 
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AGURE 1. Changes in left ventricular end-diastolic pres- 
sure (LVEDP) and ST-segment depression during the 
atrial pacing stress test before (APST I) and after 
(APST II) placebo (open bars) or L-propionylcarnitlne 
(black bars] administration. L-propionylcarnitine reduces 
myocardial ischemia as seen by a 45% reduction in left 
ventricular enckliastolic pressure immediately after 
pacing and a 10% reduction in ST-segment depression 
during pacing. Values are expressed as mean f SEM. 
l p co.05 versus control; +p ~0.05, changes during APST 
I versus changes during APST II. C q control; M = maxi- 
mal pacing; 15” = 15 seconds after pacing. 
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TABLE IV Scintigraphic Changes During Both Pacing Tests 
Placebo (n=16) APST I Postpacing Control APST II Postpacing 
LPC (n=i 5) Control Maximal (10 min) Drug Infusion Control Maximal (10 min) 
GEF Placebo 50 f 3 40 f 5 49 * 4 49+4 47 * 4 50*3 48*4 
LPC 43 f 4 43 * 4 39 f 3 39i3t 38i4 45*4* 39 * 4 
TPE Placebo 123 + 12 109 * 10 128 * 16 139i15 131 + 12 111 + 18* 136*16 
LPC 157+23 111 *II 139k15 138i17 150*15 114*13 167 f 12 
PER Placebo 2.47 f 0.22 4.04 * 0.43* 2.46 f 0.29 2.33 zt 0.23 2.27 zt 0.25 4.20 f 0.31* 2.58 f 0.30 
LPC 2.05 f 0.18 3.64 f 0.39’ 1.85i0.13 1.84 f 0.14 1.83kO.18 3.88 f 0.38* 2.19 * 0.20** 
TPF Placebo 498 f 12 286 i 16’ 509 f 14 519 f 13t 503*11 308 zt 13 500 f 15 
LPC 504+12 330*15’ 522rt13 528*13t 521 f 14 313 f 14* 497 i 16*$ 
PFR Placebo 2.22 * 0.21 3.49 + 0.43 2.14+0.19 2.05 f 0.17 2.00 * 0.22 4.05 * 0.43’ 2.13 f 0.20 
LPC 1.55kO.16 3.10 * 0.46’ 1.44*0.14 1.30 *0.15t 1.26 f 0.13t 2.87 f 0.45’ 1.53 f 0.15** 
‘p ~0.05 versus control; tp ~0.05 versus control APST I; *p ~0.05, change during APST I versus change during APST II. 
Data are mean f SEM. 
APST = atrial pacing stress test; GEF = left ventricular ejection fraction (%); PER = peak ejection rate (s-l); PFR = peak filling rate (s’); TPE = time to peak 
ejection (ms); TPF = time to peak filling (ms); other abbreviations as in Table I. 
DISCUSSION 
In the present study, the potential of LPC to reduce 
myocardial &hernia following intravenous administra- 
tion was evaluated in a double-blind, placebo-controlled 
fashion in patients with coronary artery disease. Whereas 
the anti-ischemic effects of LPC were already present 
during pacing, they were most pronounced in the im- 
mediate and late postpacing period. Immediately after 
pacing with LPC, the increase in left ventricular filling 
pressures was significantly reduced, indicating better 
preservation of compliance, as compared with results af- 
ter APST I. In addition, LPC improved scintigraphic 
measures of contractility and relaxation and prevented 
the reduction in cardiac output observed after the first 
untreated pacing test. 
So far, several animal studies have reported the abil- 
ity of LPC to improve mechanical recovery after myo- 
cardial ischemia.13~15,16Jz1,22 The present study indicates 
that LPC may have similar beneficial effects during acute 
myocardial ischemia and the early recovery phase in hu- 
mans. 
Antbchemic nroperties of LiwoiWnylcamiti- 
consumption. Although this may be true in the regional 
ischemic area, an overall metabolic effect is less likely. 
Effects of L-propionylcamitine during the early 
recovery phase: Taken together, the anti-ischemic ef- 
fects of LPC were moderate during pacing-induced 
stress, but, in contrast, more prominent during the re- 
covery phase after pacing. As such, our lindings agree 
with observations from animal ischemia-reperfusion 
studies.‘3J5 In the present study, both systolic and dias- 
tolic cardiac function and cardiac output were signifi- 
cantly enhanced during the first 10 minutes of recovery 
after pacing following LPC. This improvement was not 
mediated by changes in pre- and afterload or heart rate. 
More likely, enhanced metabolic recovery and increased 
myocardial energy stores are involved. In animal ische- 
mia-reperfusion experiments, LPC increases high-en- 
ergy phosphate concentrations and stimulates fatty acid 
oxidation during the reperfusion period.25,26 Moreover, 
through modulation of the activity of adenine nucleotide 
translocase, carnitine is likely to promote adenosine 
triphosphate transfer from the mitochondrium to the con- 
tractile urotein site. Finallv, the anaulerotic mechanism 
underlying mech&ms: In the present study, LPC did 
not affect myocardial ischemia by modulating the myo- 
cardial oxygen supply-demand ratio. In anesthetized 
dogs, 200 mg/kg of intravenous LPC results in coronary 
and peripheral vasodilation.23 Moreover, in pigs, 50 
mg/kg of LPC improves myocardial blood flow during 
reperfusion after 60 minutes of ischemia.t6 In a previ- 
ous study, we were unable to observe any acute vasodi- 
lating effects of 15 mg/kg of LPC.24 This difference in p loo- 
results between animal and human data may relate to :: 
different dosages, a different model of ischemia and ’ 
E 
d’ 
reperfusion, and the inability to measure regional coro- 
nary flow changes in our study. However, the complete 
absence of any coronary vasodilating effect of LPC in 
10 I I 
0 5 15 45 
Time (min) 
our study and the absence of changes in myocardial oxy- 
gen consumption make a drug-induced improvement in FIGURE 2. Arterial levels of total (closed circles) and 
myocardial oxygen supply unlikely. Also, LPC did not free (open circles) camitine before and after infusion 
affect the rate-pressure product or myocardial contrac- of 15 mg/kg of L-proplonylcarnitine (black bar). Both te 
tility during pacing, which indicates that the compound tal and free camitine plasma levels increased quickly 
does not interfere with myocardial oxygen demand. 
after intravenous administration after which the total 
Moreover, an increase in citric acid cycle activity should 
camitine plasma level decreased more rapidly than the 
free eamitine timma level. values are expressed as 
be accompanied by an increase in myocardial oxygen mean + SEM. 
L-PROPIONYLCARNITINE IN ISCHEMIA I.29 
of LPC whereby propionyl-CoA is converted to suc- 
cinyl-CoA, subsequently improving the citric acid flux, 
may be more effective during reperfusion and recovery, 
when oxygen is again available and the electron trans- 
port chain is free to run. 
Clinical implications: Our study indicates that LPC 
acutely reduces myocardial ischemia and improves car- 
diac function in the recovery period following a short 
period of ischemia, a modulation that is most likely me- 
diated through its metabolic properties. This alternative 
mode of action and the absence of any untoward effects 
suggest a role for LPC in modulating the functional con- 
sequences of acute myocardial ischemia nd reperfusion. 
1. Shug AL, Shmgo E. A proposed mechanism for fatty acid effects on energy me- 
tabolism of the heart. J Lab Clin Med 1973;81:21&218. 
2. Shug A, Shargo E, Bittar N, Felts JD, Koke JR. Long chain fatty acyl CoA in- 
hibition of adenine nucleotide in the ischemic myocardium. Am J Physiol 1975; 
2281689-692. 
3. Uziel G, Garavaglia B, Di Donate S. Camitine stimulation of pymvate dehy- 
dmgenase complex (PDHC) in isolated human skeletal muscle mitochondria. Mus- 
cle & Nerve 1988;11:72&724. 
4. Bremer J. Camitine-metabolism and functions. Phys Rev 1983;63:142&1480. 
5. Bieber LL. Camitine. Ann Rev Biochem 1988;57:261-283. 
6. Shug AL, Thomsen JH, Folts JD, Bittar N, Klein MI, Koke JR, Huth PJ. Changes 
in tissue levels of camitine and other metabolites during myocardial ischemia and 
anoxia. Arch B&hem Biophys 1978; 187:25-33. 
7. Spagnoli LG, Corsi M, Villashi S, Pahnieri G, Maccari F. Myocardial camitine 
deficiency in acute myocardial infarction. Lancet 1982;1:141%1420. 
8. Liedtke AJ, Nellis SH, Whitesell F. Effects of L-camitine isomers on fatty acid 
metabolism in ischemic swine hearts. Circ Res 1981;48:859-866. 
9. Felts JD, Shug AL, Koke JR, Bittar N. Protection of the ischemic dog my- 
ocardium with camitine. Am J Cardiol 1978;41:1209-1214. 
10. Fermri R, Cucchini F, Visioli 0. The metabolic effects of L-camitine in angina 
pectoris. Intern .I Cardiol 19&1;5:213-216. 
ll. Cherchi A, Lai C, Angelino F, Tmcco G, Caponnetto S, Mereto PE, Rosolen 
G, Manzoli U, Schiavoni R, Reale A, Romeo F, Rizzon P, Sorgente L, Strano A, 
Novo S, Immordino R. Effects of L-camitine on exercise tolerance in chronic sta- 
ble angina: a multicenter, double-blind, randomized, placebo controlled crossover 
study. Clirt Pharm Ther Tax 1985;23:56%572. 
l.2. Siliprandi N, Di Lisa F, Pivetta A, Miotto G, Siliprandi D. Transport and func- 
tion of L-camitine and L-pmpionylcamitine: relevance to some cardiomyopathies 
and cardiac &hernia. 2 Kardiol 1987;76(suppl 5):34-40. 
la. Paulson DJ, Trawler I, Schmidt M, Noonan J, Shug AL. Protection of the is- 
chaemic myocaniium by L-propionylcamitine: effects on the recovery of cardiac 
output after ischaemia and reperfusion, camitine transport, and fatty acid oxidation. 
Cardiovasc Res 1986;20:536-541. 
14. Di Lisa F, MenaM R, Siliprandi N. L-propionyl-camitine protection in ische- 
mic rat heart. Mel Cell Biochem 1989,88: 169-173. 
15. Liedtke AI, DeMaison L, Nellis SH. Effects of L-propionylcamitine on me- 
chanical recovery during reflow in intact hearts. Am JPhysio/ 1988;255:H169-H176. 
16. Sassen LMA, Bezstwosti K, Van der Giessen WJ, Lamers JMJ, Verdouw PD. 
L-propionylcamitine increases post-ischemic blood flow but does not affect recov- 
ay of the energy charge. Am J Physiol 1991;261:H172-H180. 
17. Remme WJ, Krauss XH, Van Hoogenhuyze DCA, Kmijssen HACM. Hemo- 
dynamic tolerability and anti-ischemic efficacy of high dose intravenous diltiazem 
in patients with normal versus impaired ventricular function. J Am Coil Cardiol 
1993;21:70!+720. 
18. Remme WJ, Van den Berg R, Mantel M, Cox PH. Van Hoogenhuyze DCA, 
Krauss XH, Storm CJ, Kmijssen HACM. Temporal relation of changes in regional 
coronary flow and myocardial lactate and nucleoside metabolism during pacing-in- 
duced ischemia. Am J Cardiol 198658: 1188-I 194. 
19. Lamers JMJ, De Jong-Stinis JT, Verdouw PD, Hiilsmann WC. On the possi- 
ble role of long chain fatty acyl camitine accumulation in producing functional and 
calcium permeability changes in membranes during myocardial ischaemia. Car- 
diovasc Res 1987:21:313-322. 
30. Magorien DJ, Shaffer PH. Bush CH, Magorien RD, Kolibash AJ, Unverferth 
DV, Bashore TM. Hemodynamic correlates for timing intervals, ejection rate and 
tilling rate derived from radionuclide angiographic volume curve. Am J Cardiol 
1984;53:567-57 1. 
21. Regitz V, Paulson DJ, Noonan J, Fleck E, Shug AL. Protection of ischemic 
myocardium by propionylcamitine taurine amide. Comparison with other camitine 
derivatives. Z Kardiol 1987;76(suppl 5):52-58. 
22. Fernui R, Ceconi C, Cure110 S, Pasini E, Visioli 0. Protective effect of L-pro- 
pionylcamitine against ischaemia and reperfusion-damage. MO/ Cell Biochem 1989; 
88:161-168. 
23. Cevese A, Schena F, Cemtti G. Short-tam hemodynamic effects of intravenous 
propionyl-L-camitine in anesthetized dogs. Cardiovasc Drug Ther 1991;5:45-56. 
24. BateIs GL, Remme WJ, Pillay M, Schi)nfeld DHW, Cox PH, Kmijssen HACM, 
Knufman NMJ. Acute improvement of cardiac function with intravenous L-propi- 
onylcamitine in man. J Cardiovasc Pharmacoi 1992;20:157-164, 
25. Ferrari R, Ceconi C, Cqnoni A, Pasini E, Boffa GM, Cure110 S, Visioli 0. 
The effect of L-propionylcamitine on the ischemic and reperfused intact my- 
ocardium and on their derived mitochondria. Cardiovasc Drugs Ther 1991;5:57-66. 
26. Shug A, Paulson D, Subramanian R, Regitz V. Protective effects of L-propi- 
onylcamitine during ischemia and reperfusion. Cardiovasc Drugs Ther 1991; 
5:77-84. 
I.30 THE AMERICAN JOURNAL OF CARDIOLOGY@ VOLUME 74 JULY 15, 1994 
